Evotec (EVT) Aandelenoverzicht
Evotec SE is wereldwijd actief als partner voor het ontdekken en ontwikkelen van geneesmiddelen voor de farmaceutische en biotechnologische industrie. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor EVT uit onze risicocontroles.
EVT Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Evotec SE Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €4.95 |
| 52 Week Hoogtepunt | €7.84 |
| 52 Week Laag | €4.00 |
| Bèta | 1.31 |
| 1 maand verandering | 7.71% |
| 3 maanden verandering | 9.18% |
| 1 Jaar Verandering | -29.80% |
| 3 jaar verandering | -77.43% |
| 5 jaar verandering | -85.81% |
| Verandering sinds IPO | -68.60% |
Recent nieuws en updates
Narratiefupdate • Jul 07
EVT: Rich P/E Will Likely Outweigh Benefits Of New Manufacturing Initiative
Analysts have raised their fair value estimate for Evotec from €4.0 to €4.5. They attribute this change to slightly adjusted discount rate assumptions, modestly higher expectations for revenue growth and profit margins, and a higher future P/E multiple in their updated models. What’s in the News for Evotec Evotec, through its Just – Evotec Biologics unit, launched J.TRAIN, a turnkey offering that lets biopharmaceutical companies deploy its proprietary continuous biologics manufacturing technology directly inside their own facilities, combining modular cleanrooms, industry-standard equipment and cGMP-compliant process automation.Narratiefupdate • Jun 23
EVT: Rich P/E Expectations Will Likely Outweigh Alliance And Governance Progress
Analysts have revised their fair value estimate for Evotec to €4.0 from €4.4, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Evotec Evotec and Almirall nominated a small molecule preclinical development candidate in medical dermatology from their multi target drug discovery alliance, focused on immune mediated inflammatory skin diseases with high unmet medical need.
Narratiefupdate • Jun 06
EVT: AI And Royalty Pipeline Will Support Future Earnings Upside
Analysts have slightly adjusted their outlook on Evotec, keeping the fair value estimate steady at €10.00 while fine tuning assumptions around discount rate, revenue growth, profit margin, and future P/E to reflect updated expectations for the business. What's in the News Evotec appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI, to lead the integration of computational science and data driven decision making across its R&D operations, positioning AI and in silico capabilities as key parts of the company’s commercial offering.Recent updates
Narratiefupdate • Jul 07
EVT: Rich P/E Will Likely Outweigh Benefits Of New Manufacturing Initiative
Analysts have raised their fair value estimate for Evotec from €4.0 to €4.5. They attribute this change to slightly adjusted discount rate assumptions, modestly higher expectations for revenue growth and profit margins, and a higher future P/E multiple in their updated models. What’s in the News for Evotec Evotec, through its Just – Evotec Biologics unit, launched J.TRAIN, a turnkey offering that lets biopharmaceutical companies deploy its proprietary continuous biologics manufacturing technology directly inside their own facilities, combining modular cleanrooms, industry-standard equipment and cGMP-compliant process automation.Narratiefupdate • Jun 23
EVT: Rich P/E Expectations Will Likely Outweigh Alliance And Governance Progress
Analysts have revised their fair value estimate for Evotec to €4.0 from €4.4, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Evotec Evotec and Almirall nominated a small molecule preclinical development candidate in medical dermatology from their multi target drug discovery alliance, focused on immune mediated inflammatory skin diseases with high unmet medical need.Narratiefupdate • Jun 06
EVT: AI And Royalty Pipeline Will Support Future Earnings Upside
Analysts have slightly adjusted their outlook on Evotec, keeping the fair value estimate steady at €10.00 while fine tuning assumptions around discount rate, revenue growth, profit margin, and future P/E to reflect updated expectations for the business. What's in the News Evotec appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI, to lead the integration of computational science and data driven decision making across its R&D operations, positioning AI and in silico capabilities as key parts of the company’s commercial offering.Narratiefupdate • May 23
EVT: Future Milestone And Royalty Stream Will Support Earnings Upside
Analysts have trimmed their price target on Evotec from €10.40 to €10.00, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that now sit slightly below prior estimates but remain within a similar range. What's in the News Evotec and Almirall nominated a small molecule preclinical development candidate for immune mediated inflammatory skin diseases, using Evotec’s AI/ML supported discovery and preclinical platforms, with potential success based milestones of up to €230 million per program plus high single digit royalties on net sales (Key Developments).
Narratiefupdate • May 04
EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside
Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).Narratiefupdate • Apr 19
EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions
Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.Narratiefupdate • Apr 05
EVT: 2025 And 2026 Revenue Guidance Will Support Future Upside
Analysts have reduced their price target on Evotec by €1.80, citing updated views on fair value, discount rate, revenue growth and profit margin assumptions, and also reflecting a revised future P/E outlook. What's in the News Evotec issued new earnings guidance for full-year 2026, targeting group revenues of about €700-780 million or €730-810 million at constant exchange rates (Key Developments).Narratiefupdate • Mar 21
EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions
Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.Narratiefupdate • Mar 07
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec to €10.40. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E multiple.Narratiefupdate • Feb 20
EVT: Kidney Disease Milestone Prospects Will Support Future Upside
Analysts have made only a very small adjustment to their Evotec price target, keeping it effectively unchanged at about €8.72. Updated assumptions for discount rate, revenue growth, profit margin and future P/E remain closely aligned with prior estimates.Narratiefupdate • Feb 06
EVT: Kidney Disease Milestones And Novo Stake Sale Will Support Future Upside
Analysts have adjusted their fair value estimate for Evotec from €8.46 to approximately €8.72, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the main factors behind the latest price target revision. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, equal to about 5% of Evotec's share capital, after previously holding 14.9 million shares or 8.4% of the company (Key Developments).Narratiefupdate • Jan 22
EVT: Milestone Progress And Share Buybacks Will Support Future Upside
Analysts have slightly adjusted their price target on Evotec to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. The fair value estimate remains steady at €8.46.Narratiefupdate • Jan 07
EVT: Milestone Payment And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for Evotec steady at €8.46, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting a largely unchanged fundamental view. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, around 5% of the company, after previously holding 14.9 million shares or 8.4% of the capital.Narratiefupdate • Dec 17
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec from €12.00 to €10.40. The revision reflects a higher perceived discount rate despite stronger expectations for revenue growth and profit margins.Narratiefupdate • Dec 03
EVT: Share Buybacks And Milestone Payment Will Support Future Upside
Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.Narratiefupdate • Aug 21
Large Pharma Partnerships And AI Platforms Will Open New Markets
The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
Nieuw narratief • Apr 30
Pharmaceutical Collaborations And Cost Savings Will Drive Excellence
Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.Analyseartikel • Nov 10
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Evotec SE ( ETR:EVT ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters...Analyseartikel • Nov 05
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb
Those holding Evotec SE ( ETR:EVT ) shares would be relieved that the share price has rebounded 32% in the last thirty...Analyseartikel • Aug 17
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Investors in Evotec SE ( ETR:EVT ) had a good week, as its shares rose 4.5% to close at €5.80 following the release of...Analyseartikel • Aug 08
Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Evotec SE ( ETR:EVT ) share price has fared very poorly over the last month, falling by a substantial 45%. The...Analyseartikel • Aug 03
We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Apr 10
Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 3.1x Evotec SE ( ETR:EVT ) is a stock worth checking out...Analyseartikel • Mar 05
These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Rendement voor aandeelhouders
| EVT | DE Life Sciences | DE Markt | |
|---|---|---|---|
| 7D | -3.8% | 7.3% | -2.5% |
| 1Y | -29.8% | -2.8% | -0.6% |
Rendement versus industrie: EVT presteerde slechter dan de German Life Sciences -sector, die het afgelopen jaar een rendement van -2.8 % opleverde.
Rendement versus markt: EVT presteerde slechter dan German Market, dat het afgelopen jaar een rendement van -0.6 % opleverde.
Prijsvolatiliteit
| EVT volatility | |
|---|---|
| EVT Average Weekly Movement | 7.6% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stabiele aandelenkoers: EVT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de German markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van EVT is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1993 | 4,526 | Christian Wojczewski | www.evotec.com |
Evotec SE is wereldwijd actief als partner voor het ontdekken en ontwikkelen van geneesmiddelen voor de farmaceutische en biotechnologische industrie. Het is actief in twee segmenten, Shared R&D en Just Evotec Biologics. Het bedrijf ontwikkelt farmaceutische producten in verschillende therapeutische gebieden, zoals oncologie, auto-immuun, kanker, diabetes, hartfalen, fibrose, immunologie, pijn en ontsteking, infectieuze, nier-, lever-, zeldzame, respiratoire, fibrotische en metabolische ziekten; centraal zenuwstelsel (CZS) en cardio-metabole aandoeningen; en gezondheid van dieren en vrouwen.
Evotec SE Samenvatting
| EVT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €879.15m |
| Inkomsten(TTM) | -€193.88m |
| Inkomsten(TTM) | €745.04m |
1.2x
P/S-verhouding-4.5x
Koers/WinstverhoudingIs EVT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| EVT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €745.04m |
| Kosten van inkomsten | €665.62m |
| Brutowinst | €79.42m |
| Overige uitgaven | €273.29m |
| Inkomsten | -€193.88m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Aug 13, 2026
| Winst per aandeel (EPS) | -1.09 |
| Brutomarge | 10.66% |
| Nettowinstmarge | -26.02% |
| Schuld/Eigen Vermogen Verhouding | 55.4% |
Hoe presteerde EVT op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/10 06:16 |
| Aandelenkoers aan het einde van de dag | 2026/07/10 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Evotec SE wordt gevolgd door 23 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Christian Ehmann | Berenberg |
| Michael Ryskin | BofA Global Research |
| Peter Verdult | Citigroup Inc |